In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unum Therapeutics Inc (UMRX), with a price target of $18. The company’s shares closed yesterday at $4.41, close to its 52-week low of $3.60.
Fein wrote:
“Our price target of $18/share is based on an equally-weighted composite of: (a) $18.1/share, as a 25x multiple of taxed and diluted $7.68 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.7/share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.0% and a 45.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Unum Therapeutics Inc with a $18 average price target.
See today’s analyst top recommended stocks >>
Based on Unum Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.6 million. In comparison, last year the company had a GAAP net loss of $6.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies.
